ALNY
Price
$242.61
Change
+$0.64 (+0.26%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
30.64B
7 days until earnings call
EXEL
Price
$37.21
Change
+$0.43 (+1.17%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
10.05B
19 days until earnings call
Ad is loading...

ALNY vs EXEL

Header iconALNY vs EXEL Comparison
Open Charts ALNY vs EXELBanner chart's image
Alnylam Pharmaceuticals
Price$242.61
Change+$0.64 (+0.26%)
Volume$13.35K
Capitalization30.64B
Exelixis
Price$37.21
Change+$0.43 (+1.17%)
Volume$37K
Capitalization10.05B
ALNY vs EXEL Comparison Chart
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. EXEL commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a StrongBuy and EXEL is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ALNY: $241.97 vs. EXEL: $36.74)
Brand notoriety: ALNY: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 79% vs. EXEL: 96%
Market capitalization -- ALNY: $30.64B vs. EXEL: $10.05B
ALNY [@Biotechnology] is valued at $30.64B. EXEL’s [@Biotechnology] market capitalization is $10.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileEXEL’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • EXEL’s FA Score: 1 green, 4 red.
According to our system of comparison, EXEL is a better buy in the long-term than ALNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 3 TA indicator(s) are bullish while EXEL’s TA Score has 6 bullish TA indicator(s).

  • ALNY’s TA Score: 3 bullish, 8 bearish.
  • EXEL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, EXEL is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а +4.98% price change this week, while EXEL (@Biotechnology) price change was +1.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

ALNY is expected to report earnings on Jul 31, 2025.

EXEL is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($30.6B) has a higher market cap than EXEL($10.1B). EXEL YTD gains are higher at: 10.330 vs. ALNY (2.830). EXEL has higher annual earnings (EBITDA): 719M vs. ALNY (-178.85M). ALNY has more cash in the bank: 2.7B vs. EXEL (1.11B). EXEL has less debt than ALNY: EXEL (191M) vs ALNY (1.3B). ALNY (2.25B) and EXEL (2.17B) have equivalent revenues.
ALNYEXELALNY / EXEL
Capitalization30.6B10.1B303%
EBITDA-178.85M719M-25%
Gain YTD2.83010.33027%
P/E RatioN/A20.88-
Revenue2.25B2.17B104%
Total Cash2.7B1.11B243%
Total Debt1.3B191M679%
FUNDAMENTALS RATINGS
ALNY vs EXEL: Fundamental Ratings
ALNY
EXEL
OUTLOOK RATING
1..100
1712
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
2623
SMR RATING
1..100
10041
PRICE GROWTH RATING
1..100
5840
P/E GROWTH RATING
1..100
10089
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (75) in the Biotechnology industry is in the same range as ALNY (99). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

EXEL's Profit vs Risk Rating (23) in the Biotechnology industry is in the same range as ALNY (26). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for ALNY (100). This means that EXEL’s stock grew somewhat faster than ALNY’s over the last 12 months.

EXEL's Price Growth Rating (40) in the Biotechnology industry is in the same range as ALNY (58). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

EXEL's P/E Growth Rating (89) in the Biotechnology industry is in the same range as ALNY (100). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYEXEL
RSI
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
54%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
66%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
60%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
64%
Declines
ODDS (%)
Bearish Trend 9 days ago
67%
Bearish Trend 21 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 2 days ago
54%
View a ticker or compare two or three
Ad is loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EKWAX83.97N/A
N/A
Allspring Precious Metals A
NBPBX44.23N/A
N/A
Neuberger Berman Large Cap Value Adv
THCRX24.44N/A
N/A
Thornburg Small/Mid Cap Growth R3
CDGRX11.20N/A
N/A
Copeland Dividend Growth Fund Class A
CBBZX6.08N/A
N/A
AB Relative Value Z

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with IONS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
+2.20%
IONS - ALNY
52%
Loosely correlated
+0.24%
ATRA - ALNY
44%
Loosely correlated
+2.37%
SGMO - ALNY
42%
Loosely correlated
-2.98%
ARGX - ALNY
41%
Loosely correlated
-0.87%
VXRT - ALNY
40%
Loosely correlated
+1.15%
More

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.71%
SRPT - EXEL
36%
Loosely correlated
+0.30%
ALNY - EXEL
34%
Loosely correlated
+2.20%
TECH - EXEL
33%
Poorly correlated
+2.20%
MRSN - EXEL
32%
Poorly correlated
+2.39%
ORMP - EXEL
32%
Poorly correlated
+0.66%
More